Let’s look at the key reasons that are pushing Ocular Therapeutix Inc (OCUL) to new highs

Ocular Therapeutix Inc (NASDAQ: OCUL) kicked off on Friday, up 3.17% from the previous trading day, before settling in for the closing price of $8.53. Over the past 52 weeks, OCUL has traded in a range of $4.79-$11.77.

During the last 5-year period, the sales growth of Healthcare Sector giant was 100.53%. While this was happening, its average annual earnings per share was recorded 0.62%. With a float of $134.13 million, this company’s outstanding shares have now reached $157.75 million.

Let’s determine the extent of company efficiency that accounts for 274 employees. In terms of profitability, gross margin is 91.16%, operating margin of -269.83%, and the pretax margin is -303.95%.

Ocular Therapeutix Inc (OCUL) Breakdown of a Key Holders of the stock

Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Ocular Therapeutix Inc is 15.79%, while institutional ownership is 73.28%. The most recent insider transaction that took place on Feb 24 ’25, was worth 147,533. In this transaction an insider of this company sold 21,475 shares at a rate of $6.87, taking the stock ownership to the 3,520,318 shares. Before that another transaction happened on Feb 24 ’25, when Company’s Chief Scientific Officer sold 3,061 for $6.87, making the entire transaction worth $21,029. This insider now owns 265,998 shares in total.

Ocular Therapeutix Inc (OCUL) Recent Fiscal highlights

According to the Wall Street analysts, stocks earnings will be around 0.62% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.84% during the next five years compared to 8.51% growth over the previous five years of trading.

Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators

Take a look at Ocular Therapeutix Inc’s (OCUL) current performance indicators. Last quarter, stock had a quick ratio of 10.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 22.00.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.27 in one year’s time.

Technical Analysis of Ocular Therapeutix Inc (OCUL)

Looking closely at Ocular Therapeutix Inc (NASDAQ: OCUL), its last 5-days average volume was 1.18 million, which is a drop from its year-to-date volume of 1.37 million. As of the previous 9 days, the stock’s Stochastic %D was 91.09%. Additionally, its Average True Range was 0.52.

During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 75.09%, which indicates a significant decrease from 95.15% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 45.53% in the past 14 days, which was lower than the 72.31% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $7.40, while its 200-day Moving Average is $8.52. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $8.97. Second resistance stands at $9.13. The third major resistance level sits at $9.37. If the price goes on to break the first support level at $8.56, it is likely to go to the next support level at $8.32. Now, if the price goes above the second support level, the third support stands at $8.16.

Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats

The company with the Market Capitalisation of 1.40 billion has total of 159,287K Shares Outstanding. Its annual sales at the moment are 63,720 K in contrast with the sum of -193,510 K annual income. Company’s last quarter sales were recorded 17,080 K and last quarter income was -48,390 K.